Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study".

Trial Profile

Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study".

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms COOPERATE-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2017.
    • 20 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2017.
    • 12 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top